Categories
Business

Double mutation Covid variant in India might unfold to different nations, physician says

The double mutation of a Covid-19 variant discovered in India is extremely worrying – and, according to Dr. Kavita Patel, a non-resident Brookings Institution scholar, spread to other countries.

“It’s something that should be watched very closely and that won’t be limited to India. It’s something that we will likely see around the world, as we have with other variants,” she told CNBCs on Monday “Street Signs Asia”.

The Indian Ministry of Health said last week that a variant with two mutations – known as E484Q and L452R – was found in the country. The mutations aren’t new, but the variant in India carries both – something that has not been seen in other variants.

The mutations could make the virus more contagious and better bypass the body’s defenses.

A health worker delivers a dose of COVID-19 vaccine at a clinic in Bhopal, India on March 25, 2021.

STR | Xinhua News Agency | Getty Images

“This double mutation, number one, is incredibly serious. Number two, it’s probably just the tip of the iceberg in what we’d be concerned about in Asia,” said Patel, who is also a former Obama administration official.

She said the mutations could lead to re-infections because the body’s immune system doesn’t recognize them and therefore can’t fight them effectively.

Patel also said she would be concerned about the effects of the mutation if she were an Asian health agency and think about ways to get vaccines as many people as possible.

Indian authorities said that Covid variants, including the double mutation strain, have not been detected in large enough numbers to explain the increase in new infections.

Categories
Business

Extra EU international locations halt AstraZeneca shot as EMA opinions uncomfortable side effects

An Army health worker prepares a dose of Covishield, AstraZeneca / Oxford’s Covid-19 coronavirus vaccine from the Indian Serum Institute at an Army hospital in Colombo on January 29, 2021.

Sign S. Kodikara | AFP | Getty Images

LONDON – Two other countries decided on Tuesday to suspend use of the AstraZeneca vaccine in Europe amid blood clot concerns as regulators conducted a new side effects review.

Sweden and Latvia announced Tuesday morning that they are suspending the rollout of the AstraZeneca vaccine developed with Oxford University. Portugal, Luxembourg and Slovenia decided to stop using the shot on Monday evening. Earlier in the day, Germany, France, Italy and Spain also joined the group of nations that stopped using the vaccine.

So far, 13 countries in the European Union have made this decision, while a few others have stopped using individual lots of the AstraZeneca vaccine. Austria first decided last week after the death of a 49-year-old woman who received this vaccine to stop using a certain batch of AstraZeneca shots.

“The benefits still outweigh the risks.”

The European health authority has insisted that “the benefits of the AstraZeneca vaccine in preventing Covid-19, with the associated risk of hospitalization and death, outweigh the risks of side effects”.

In a statement on Monday, the European Medicines Agency said it would “look further into the information” and called an extraordinary meeting on Thursday on the subject. The institution then reiterated its position during a press conference on Tuesday.

“There is currently no evidence that vaccination caused these conditions,” said Emer Cooke, director of the European Medicines Agency. “The benefits still outweigh the risks, but this is a serious problem and requires serious and detailed scientific assessment. We are currently involved in that.”

She added, “We are concerned that this could affect vaccine confidence … but our job is to make sure the products we approve are safe.”

Of course, we need speed, not just for the economy, but above all for the health of our citizens, but at the same time we need security.

Paolo Gentiloni

EU commissioner for the economy

The World Health Organization has urged nations to continue their vaccination campaigns with the AstraZeneca vaccine and Oxford University.

A number of EU countries have spoken out in favor of the shot. In Belgium, Health Minister Frank Vandenbroucke said on Monday that interrupting use was “irresponsible”. While the authorities in the Czech Republic have also announced that they will continue to administer the vaccine.

Outside the EU, Canada, Australia and the UK have also joined forces to support AstraZeneca.

According to the European Center for Disease Prevention and Control, more than 6 million doses of the AstraZeneca shot have been administered in the EU to date.

AstraZeneca announced on Sunday that of the 17 million people vaccinated in the EU and the UK, 15 had deep vein thrombosis events and 22 cases of pulmonary embolism. This is based on data received as of March 8th.

“This is much less than expected to occur naturally in a general population of this size and it is similar to other approved Covid-19 vaccines,” the company said in a statement.

Concerns about the vaccine could jeopardize the EU’s goal of vaccinating 70% of the adult population by the end of the summer. The AstraZeneca vaccine has proven popular in Europe so far because it is cheaper than its competitors and easier to store. This could then possibly delay the economic recovery in the region.

“Of course we need speed, not only for the economy, but above all for the health of our citizens, but at the same time we need security,” said Paolo Gentiloni of the European Commission at a press conference on Monday.

He added that the precautionary measures were “justified” and that the EMA review should “keep our EU citizens safe”.

Categories
Health

Docs react as EU international locations droop shot

A healthcare worker prepares a syringe with the dose of AstraZeneca Covid-19 in Coria City Hospital, Spain.

Gustavo Valiente | SOPA pictures | LightRocket via Getty Images

LONDON – Health professionals are disappointed and confused about the numerous suspensions of the coronavirus vaccine developed by AstraZeneca and Oxford University. They warn that there is not enough data to justify these decisions.

Germany, France, Italy and Spain joined a rapidly growing list of European countries on Monday that are stopping use of the vaccine as a precautionary measure after reports of blood clots.

Other countries such as Austria have temporarily stopped using certain lots of the Oxford-AstraZeneca vaccine. Thailand became the first Asian nation on Friday to stop using the shot because of safety concerns.

The UK, Canada and Australia, which continue to use the vaccine, are among the countries trying to reassure citizens about its benefits.

The World Health Organization, the European Medicines Agency and the International Society on Thrombosis and Hemostasis have recommended that countries continue to use the Oxford-AstraZeneca vaccine.

There is still no evidence of data to really justify these decisions.

Michael Head

Senior Research Fellow in Global Health at the University of Southampton

“The decisions made by France, Germany and other countries look amazing,” said Dr. Michael Head, Senior Research Fellow in Global Health at the University of Southampton, UK

“The data we have suggests that the number of blood clot-related adverse events is the same (and possibly fewer) in vaccinated groups compared to non-vaccinated populations,” he continued.

“Pausing the introduction of a vaccine during a pandemic has consequences. This creates delays in protecting people and a possible delay in vaccine due to people who have seen the headlines and are understandably concerned. There is still no evidence of data that really justify these decisions, “added Head.

WHO experts will meet on Tuesday to review the safety of the shot.

The European Medicines Agency, which also evaluates the drug’s safety, says there is no evidence that it causes blood clots and believes the benefits of the vaccine “continue to outweigh the risks”.

What did AstraZeneca say?

More than 17 million people in the European Union and the United Kingdom have received a dose of the Oxford AstraZeneca vaccine. As of last week, fewer than 40 cases of blood clots had been reported, AstraZeneca said in a statement.

The pharmaceutical company said that 15 events involving deep vein thrombosis and 22 events involving pulmonary embolism were reported among those vaccinated in the EU and the United Kingdom.

“This is much less than expected to occur naturally in a general population of this size, and it is similar to other approved COVID-19 vaccines,” said AstraZeneca.

The EMA has also said that the data available so far showed that the number of blood clots in vaccinated people is no higher than in the general population.

A bottle of the AstraZeneca vaccine.

Igor Petyx | KONTROLAB | LightRocket via Getty Images

Europe’s caution regarding the drug has exacerbated the problems of the battered vaccination campaign in the region and comes at a time when the German health department has warned that a third wave of coronavirus infections has already begun.

Dr. Stephen Griffin, associate professor in the University of Leeds School of Medicine, said the news that many countries in Europe had suspended the introduction of the Oxford-AstraZeneca vaccine was “disappointing”.

“With many European countries currently experiencing a resurgence of SARS-CoV2 infections and still lagging behind on adoption, the importance of continuing vaccination programs and the harm done by people having access to one should not be underestimated Vaccine denied will do. ” even the worst-case scenarios probably outweigh the odds, if at some point a connection to the coagulation disorders is found, “said Griffin.

“It should also be noted that nationwide gestures like these inevitably create hesitation or a more extreme sentiment towards vaccines and further undermine vaccination efforts,” he added.

How does the vaccine work?

The Oxford AstraZeneca vaccine is designed to prevent coronavirus in people aged 18 and over. It’s made up of an adenovirus that has been modified to contain the gene to make a protein from SARS-CoV-2, the virus that causes Covid-19. Therefore, the vaccine does not contain a virus and cannot cause Covid.

The most common side effects of the shot are typically mild or moderate and get better within a few days after vaccination.

In late clinical studies, the AstraZeneca Oxford shot was found to have an average of 70% effectiveness in protecting against the virus.

“We are carefully reviewing the reports, but the evidence available does not suggest that the vaccine is the cause,” said Dr. Phil Bryan, Vaccine Safety Director for the UK Medicines and Health Products Regulatory Agency.

“Blood clots can occur naturally and are not uncommon. In the UK, more than 11 million doses of the AZ vaccine have now been given and the number of blood clots reported after the vaccine is no more than the number that would have occurred naturally in the UK of the vaccinated population, “he continued.

“We are working closely with international colleagues to understand the global safety experience of COVID-19 vaccines and to share safety data and reports quickly. People should still get their COVID-19 vaccine when prompted,” said Bryan.

Categories
Business

These international locations are open to vaccinated vacationers — however not their youngsters

As more and more countries lift travel restrictions on vaccinated people, the world is slowly opening up to travelers again.

So travelers without children.

To date, no Covid-19 vaccine has been approved for use in children, said Dr. Sharon Nachman, director of the Pediatric Infectious Disease Department at Stony Brook Children’s Hospital.

Clinical trials vary for children, and factors like dosage levels and pre-existing vaccination schedules for children need to be evaluated before vaccines are approved for them, she said.

The countries are opening up to vaccinated travelers

Countries like Estonia and Seychelles have opened borders and removed quarantine requirements for vaccinated travelers. Greece and Thailand have indicated that similar measures are in the works.

Other countries allow vaccination exemptions for certain types of travelers. Georgia requires you to enter by air from certain Slovenian policy only applies to those who have taken vaccines made in America and Europe.

Slovenia is opening its borders to travelers who have received vaccines from Pfizer-BioNTech, Moderna and AstraZeneca.

Mathew Roberts Photography – www.matroberts.co.uk | Moment | Getty Images

Iceland only allows vaccinated travelers to bypass quarantine requirements if they are currently allowed access – and most people do not.

Experiments with children have started but will take time

Covid-19 vaccines from Moderna, Johnson & Johnson and Oxford-AstraZeneca are approved for people aged 18 and over. People aged 16 and over can take the Pfizer-BioNTech vaccine.

Vaccination trials in children have begun, but the most distant ones affect older children and adolescents, said Dr. Jeremy Levin, chairman of the Biotechnology Innovation Organization, a trade association for the biotech industry.

It’s important to understand that studies in children may have to be different.

DR. Jeremy Levin

Chairman of the BIO

“Pfizer and Moderna are testing their vaccines on children 12 years and older and may have data by summer,” Levin told CNBC Global Traveler. “Johnson & Johnson, Novavax and AstraZeneca are further behind but also plan to test their vaccines in children.”

Last month, Oxford University announced that AstraZeneca studies would begin for children 6 years and older. Johnson & Johnson is also starting vaccination trials first in older children, followed by infants and newborns Shortly thereafter, the New York Times reported last month.

Russia is requesting permission to conduct trials of its Sputnik V coronavirus vaccine in children, although it has not yet set specific age groups, Levin said.

Andrey Rudakov | Bloomberg | Bloomberg | Getty Images

“It’s important to understand that studies in children may have to be different,” Levin said. “These studies may take longer to read because adverse effects of Covid-19 are less common in this population.”

Infected children are often asymptomatic and do not tend to get seriously ill from Covid-19. Child deaths are also rare.

When are children vaccinated?

Vaccinations are not expected in time for the summer travel season, but they are expected to be available to students in the fall, said Dr. Anthony Fauci, White House Chief Medical Officer.

“I’m not sure if it’s exactly the first day of school opening, but it’s pretty close,” he said on NBC’s Meet the Press on February 28.

Elementary school children have to wait a little longer.

“If you project realistically, when we will be able to get enough data to say that elementary school children can be vaccinated … I would think that this would be the end of the year at the earliest and would very likely be the first Quarter of 2022, “said Fauci.

Fauci said companies are testing vaccines in a process known as “age de-escalation”. Older children are tested first and then gradually worked through to babies.

“Almost all vaccine companies have to start learning from infants,” Nachman said, although she called conducting age-group studies “something.” [of] an artificial plan “which is” not prescribed by science “.

“In many studies there is no evidence of increased safety … as we get older and escalate,” she said. “The result is that we are not protecting children and their families, but increasing their risk by not getting them [vaccinated] earlier.”

Are there exceptions made for children to travel?

In Slovenia, children under the age of 13 can avoid quarantine and testing requirements when crossing the border “with a close family member who has not been quarantined,” said Sabina Langus Boc of the Slovenian Ministry of the Interior.

However, most countries that have relaxed travel restrictions for vaccinated travelers do not allow exceptions for unvaccinated children. However, it could happen if countries hit by catastrophic losses in tourism revenues try to attract family vacationers this summer.

“Countries that are exempting children from vaccination do so when data are not available,” Levin said. “It is important to know that we know that children can and will be harmed by Covid-19.”

Family travel this summer

While vaccination guidelines may not give children opportunities to travel abroad this summer, families can consider destinations like the Maldives and Mexico that are open to everyone – vaccinated or not.

New destinations are expected to open to more travelers as vaccination campaigns continue around the globe. On March 25th, the Seychelles will welcome all visitors – regardless of vaccination status – with the expectation that the island nation will achieve herd immunity this month.

Amid an aggressive vaccination rollout that began in January, Seychelles opened to vaccinated travelers before it was announced that all travelers would be welcomed on March 25th.

Westend61 | Westend61 | Getty Images

Families can also consider one of the few island hotspots that have kept Covid infection rates low if they’re ready to “vacation on the spot” together.

However, most people are expected to travel domestically this summer, a trend that applies from the US to China and Saudi Arabia. In a new report by TripAdvisor, released in January, domestic travel was named one of five trends to watch this year.

Others may stay at home until medical authorities deem it safe to travel again. The Centers for Disease Control and Prevention is currently advising people to “postpone travel and stay home to protect themselves and others from Covid-19, even if they are vaccinated”.

Categories
Health

AstraZeneca Covid vaccine suspended in some international locations over blood clot fears

A health worker holds a box of the AstraZeneneca vaccine at the Bamrasnaradura Institute for Infectious Diseases in Nonthaburi Province on the outskirts of Bangkok.

Chaiwat subprasome | SOPA pictures | LightRocket via Getty Images

LONDON – The coronavirus vaccine developed by AstraZeneca and Oxford University has been exposed in a number of countries in Europe and Asia after reports of blood clots in some vaccinated people.

However, many other nations have defended their use of the shot and announced that they will continue their respective vaccination campaigns.

Thailand became the first Asian country to stop using the sting on Friday due to safety concerns, shortly after Denmark announced a two-week hiatus from its nationwide rollout after reports of blood clots and a death.

In a setback to the battered vaccination campaign in Europe, seven other countries have also suspended the use of the Oxford-AstraZeneca shot: Norway, Iceland, Bulgaria, Luxembourg, Estonia, Lithuania and Latvia.

Austria and Italy have since announced that they will no longer use certain batches of the vaccine as a precaution.

The European Medicines Agency, the European Medicines Agency, stressed Thursday that there was no evidence that the shot was causing blood clots, adding that the vaccine’s benefits “continue to outweigh the risks”.

The EMA acknowledged that some member states had stopped using the Oxford-AstraZeneca shot, but said vaccinations may continue to be given while a clot investigation is ongoing.

By Wednesday, around 5 million people in Europe had received the Oxford-AstraZeneca vaccine. Of this number, 30 cases of so-called “thromboembolic events” were reported. These cases relate to blood clots that form in the blood vessels and block blood flow.

AstraZeneca said the vaccine has been extensively studied in Phase 3 trials and peer-reviewed data confirms the shot is “generally well tolerated.”

Why do countries pause vaccination campaigns?

The Thai Ministry of Health announced on Friday that it would temporarily postpone the use of the Oxford-AstraZeneca vaccine. The shot is reportedly labeled a “good vaccine” but is said to be suspended for safety investigation.

Kiattiphum Wongjit, permanent secretary of the health ministry, said the Southeast Asian country may suspend its vaccination campaign as it has largely controlled a second wave of Covid cases through quarantines and border controls, according to Reuters.

A press conference will be held on March 12, 2021 in Bangkok, Thailand, to temporarily suspend the introduction of vaccination against AstraZeneca Covid-19 in Thailand.

Xinhua | Rachen Sageamsak via Getty Images

The country of nearly 70 million people has so far recorded around 26,600 cases and 85 deaths, according to Johns Hopkins University.

The decision of Thailand to suspend the planned launch of the Oxford-AstraZeneca vaccine, which was due to start on Friday, was made following the decision of the Danish health authority.

“It is important to emphasize that we have not decided against the AstraZeneca vaccine, but are putting it on hold,” said Soren Brostrom, director of the National Health Agency in Denmark, on Thursday.

“There is good evidence that the vaccine is both safe and effective. However, we and the Danish Medicines Agency need to respond to reports of possible serious side effects from both Denmark and other European countries.”

Many high-income countries have chosen to continue rolling out the Oxford-AstraZeneca vaccine for safety reasons.

The UK, France, Australia, Canada and Mexico are among the nations that have tried to reassure citizens about the vaccine’s benefits and have announced that they will continue their respective vaccination campaigns.

“An analysis of our safety data of more than 10 million records has shown no evidence of an increased risk of pulmonary embolism or deep vein thrombosis in any particular age group, gender, batch or country with AstraZeneca COVID-19 vaccine.” said an AstraZeneca spokesman.

“In fact, the number of these types of events observed is significantly lower in vaccinated people than would be expected in the general population.”

What do the experts say?

The EMA’s safety committee is investigating the problem, but has determined that there is currently no evidence that the vaccination caused blood clots. It should be noted that these are not listed as side effects of this vaccine.

The European Medicines Agency also noted that the data available so far showed that the number of blood clots in vaccinated people is no higher than in the general population.

“Reports of previously received blood clots are no greater than the numbers that would have occurred naturally in the vaccinated population,” said Dr. Phil Bryan, Vaccine Safety Director for the UK Medicines and Health Products Agency.

“Public safety will always come first. We will continue to examine this issue carefully, but the evidence available does not confirm the vaccine is the cause. People should still get their COVID-19 vaccine when prompted become.” Said Bryan.

Peter Brownsea, a Southampton resident, receives the Oxford / AstraZeneca Covid-19 vaccine from a member of the Hampshire Fire and Rescue Service at a temporary vaccination center at the Basingstoke Fire Station in Hampshire, southern England, while crews continue to answer 999 emergency calls.

Andrew Matthews | AFP | Getty Images

Stephen Evans, Professor of Pharmacoepidemiology at the London School of Hygiene & Tropical Medicine, said: “The problem with spontaneous reports of suspected vaccine side effects is the tremendous difficulty in distinguishing a causal effect from a coincidence.”

“This is especially true when we know that Covid-19 disease is very closely related to blood clotting and that there have been hundreds, if not many thousands of deaths caused by blood clotting as a result of Covid-19 disease. That first thing to do is to be absolutely sure that the clots were not caused by any other cause, including Covid-19, “added Evans.

How does the vaccine work?

The Oxford AstraZeneca vaccine is designed to prevent coronavirus in people aged 18 and over. It’s made up of an adenovirus that has been modified to contain the gene to make a protein from SARS-CoV-2, the virus that causes Covid-19.

The most common side effects of the shot, which does not contain the virus and cannot cause Covid, are typically mild or moderate and improve within a few days after vaccination.

In late clinical studies, the AstraZeneca-Oxford shot was found to have an average of 70% effectiveness in protecting against the virus.

A recent study by Oxford researchers found that the Covid vaccine was 76% effective at preventing symptomatic infection for three months after a single dose and that the effectiveness rate actually increased with a longer interval between the first and second dose.

– CNBC’s Holly Ellyatt contributed to this report.

Categories
Business

European Nations Droop Use of AstraZeneca Photographs Over Worries About Blood Clots

Italy’s suspension of another batch was tied to a man in Sicily who died after receiving his shot. It is unclear whether a blood clot was involved.

The vaccine manufactured by AstraZeneca has been injected into more than 142,000 people in Denmark, which has a population of around six million.

The Danish Health Minister Magnus Heunicke said on Twitter that it was “currently not possible to determine whether there is a connection”. He added: “We acted early, it needs a thorough investigation.”

Denmark had already cut the target for the completion of its vaccination campaign, partly due to delivery delays. The safety break will delay it further.

AstraZeneca’s vaccine was screened for potential safety issues over the past year while being tested in clinical trials. Two vaccinated volunteers in the UK developed neurological symptoms related to transverse myelitis, an inflammatory syndrome that affects the spinal cord and is often caused by viral infections.

These concerns temporarily put the vaccine to a halt around the world, but the investigation ultimately found no evidence to link the symptoms to the vaccine. One of the sick participants was later found to have an undiagnosed case of multiple sclerosis.

Since then, more than 70 countries have approved the vaccine, with the exception of the United States, where regulators are waiting for data from a large clinical trial expected in the next few weeks. A Food and Drug Administration decision to approve AstraZeneca’s vaccine is likely more than a month away.

The largest real world data on the safety of the vaccine comes from the UK, which had given 9.7 million doses in the last month. The UK Medicines Agency, the regulator of medicines and health products, said: “The number and types of suspected adverse reactions reported to date are not uncommon when compared to other types of vaccines routinely used.”

Rebecca Robbins reported from Bellingham, Washington, and Thomas Erdbrink from Amsterdam. Jason Horowitz and Emma Bubola reported from Italy, Benjamin Mueller from London and Denise Grady from New York.

Categories
Business

If Poor Nations Go Unvaccinated, a Examine Says, Wealthy Ones Will Pay

Durch die Monopolisierung der Impfstoffversorgung gegen Covid-19 drohen den reichen Nationen mehr als eine humanitäre Katastrophe: Die daraus resultierenden wirtschaftlichen Verwüstungen werden die wohlhabenden Länder fast genauso hart treffen wie die in den Entwicklungsländern.

Dies ist die entscheidende Erkenntnis aus einer akademischen Studie, die am Montag veröffentlicht werden soll. Im extremsten Szenario – mit reichen Nationen, die bis Mitte dieses Jahres vollständig geimpft waren, und armen Ländern, die weitgehend geschlossen sind – kommt die Studie zu dem Schluss, dass die Weltwirtschaft Verluste von mehr als 9 Billionen US-Dollar erleiden würde, eine Summe, die über der Jahresproduktion Japans und Deutschlands liegt kombiniert.

Fast die Hälfte dieser Kosten würde von wohlhabenden Ländern wie den Vereinigten Staaten, Kanada und Großbritannien übernommen.

In dem Szenario, das Forscher als am wahrscheinlichsten bezeichnen und in dem Entwicklungsländer bis Ende des Jahres die Hälfte ihrer Bevölkerung impfen, würde die Weltwirtschaft immer noch einen Schlag zwischen 1,8 und 3,8 Billionen US-Dollar absorbieren. Mehr als die Hälfte der Schmerzen würde sich auf wohlhabende Länder konzentrieren.

Die von der Internationalen Handelskammer in Auftrag gegebene Studie kommt zu dem Schluss, dass eine gerechte Verteilung der Impfstoffe im wirtschaftlichen Interesse jedes Landes liegt, insbesondere derjenigen, die am stärksten vom Handel abhängen. Es ist eine Zurechtweisung für die weit verbreitete Auffassung, dass der Austausch von Impfstoffen mit armen Ländern lediglich eine Form der Wohltätigkeit ist.

“Natürlich sind alle Volkswirtschaften miteinander verbunden”, sagte Selva Demiralp, Wirtschaftswissenschaftlerin an der Koc-Universität in Istanbul, die zuvor bei der Federal Reserve in Washington gearbeitet hatte, und eine der Autoren der Studie. “Keine Volkswirtschaft wird vollständig wiederhergestellt, wenn die anderen Volkswirtschaften nicht wiederhergestellt werden.”

Frau Demiralp merkte an, dass eine globale philanthropische Initiative namens ACT Accelerator, die darauf abzielt, Entwicklungsländern Pandemieressourcen zur Verfügung zu stellen, Verpflichtungen in Höhe von weniger als 11 Milliarden US-Dollar für ein Ziel von 38 Milliarden US-Dollar eingegangen ist. Die Studie legt die wirtschaftlichen Gründe für das Schließen der Lücke dar. Die verbleibenden 27 Milliarden US-Dollar mögen auf den ersten Blick wie eine enorme Summe aussehen, sind aber im Vergleich zu den Kosten für die Fortsetzung der Pandemie eine Kleinigkeit.

Die alltägliche Idee, dass die Pandemie weder Grenzen noch Rassen- und Klassenunterschiede respektiert, wurde von Unternehmensleitern und Experten gefördert. Dieses tröstliche Konzept wurde durch die Tatsache widerlegt, dass Covid-19 den Tod und die Zerstörung von Lebensgrundlagen bei Niedriglohn-Servicemitarbeitern und insbesondere bei rassistischen Minderheiten trainiert hat, während Angestellte weitgehend sicher von zu Hause aus arbeiten konnten, und einige andere der reichsten Menschen der Welt können die Pandemie auf Yachten und Privatinseln ausreiten.

Aber im Bereich des internationalen Handels gibt es kein Versteck vor dem Coronavirus, wie die Studie zeigt. Stattdessen gibt es globale Lieferketten, die die Teile für die Industrie produzieren und die weiterhin gestört werden, solange das Virus eine Kraft bleibt.

Ein Team von Wirtschaftswissenschaftlern der Koc University, der Harvard University und der University of Maryland untersuchte Handelsdaten in 35 Branchen in 65 Ländern und untersuchte ausführlich die wirtschaftlichen Auswirkungen einer ungleichen Impfstoffverteilung.

Covid19 Impfungen >

Antworten auf Ihre Impfstofffragen

Wenn ich in den USA lebe, wann kann ich den Impfstoff bekommen?

Während die genaue Reihenfolge der Impfstoffempfänger von Staat zu Staat unterschiedlich sein kann, werden die meisten Ärzte und Bewohner von Langzeitpflegeeinrichtungen an erster Stelle stehen. Wenn Sie verstehen möchten, wie diese Entscheidung getroffen wird, hilft dieser Artikel.

Wann kann ich nach der Impfung wieder zum normalen Leben zurückkehren?

Das Leben wird erst wieder normal, wenn die Gesellschaft als Ganzes ausreichend Schutz gegen das Coronavirus erhält. Sobald die Länder einen Impfstoff zugelassen haben, können sie in den ersten Monaten höchstens einige Prozent ihrer Bürger impfen. Die nicht geimpfte Mehrheit bleibt weiterhin anfällig für Infektionen. Eine wachsende Anzahl von Coronavirus-Impfstoffen zeigt einen robusten Schutz vor Krankheit. Es ist aber auch möglich, dass Menschen das Virus verbreiten, ohne zu wissen, dass sie infiziert sind, weil sie nur leichte oder gar keine Symptome haben. Wissenschaftler wissen noch nicht, ob die Impfstoffe auch die Übertragung des Coronavirus blockieren. Selbst geimpfte Menschen müssen vorerst Masken tragen, Menschenmassen in Innenräumen meiden und so weiter. Sobald genügend Menschen geimpft sind, wird es für das Coronavirus sehr schwierig, gefährdete Personen zu finden, die infiziert werden können. Je nachdem, wie schnell wir als Gesellschaft dieses Ziel erreichen, könnte sich das Leben im Herbst 2021 einem normalen Zustand nähern.

Muss ich nach der Impfung noch eine Maske tragen?

Ja, aber nicht für immer. Die beiden Impfstoffe, die möglicherweise in diesem Monat zugelassen werden, schützen die Menschen eindeutig vor einer Krankheit mit Covid-19. Die klinischen Studien, die diese Ergebnisse lieferten, waren jedoch nicht darauf ausgelegt, festzustellen, ob geimpfte Personen das Coronavirus noch verbreiten können, ohne Symptome zu entwickeln. Das bleibt eine Möglichkeit. Wir wissen, dass Menschen, die von Natur aus mit dem Coronavirus infiziert sind, es verbreiten können, ohne Husten oder andere Symptome zu haben. Die Forscher werden diese Frage bei der Einführung der Impfstoffe intensiv untersuchen. In der Zwischenzeit müssen sich selbst geimpfte Menschen als mögliche Spreizer vorstellen.

Wird es wehtun? Was sind die Nebenwirkungen?

Der Impfstoff gegen Pfizer und BioNTech wird wie andere typische Impfstoffe als Schuss in den Arm abgegeben. Die Injektion unterscheidet sich nicht von denen, die Sie zuvor erhalten haben. Zehntausende Menschen haben die Impfstoffe bereits erhalten, und keiner von ihnen hat ernsthafte gesundheitliche Probleme gemeldet. Einige von ihnen haben jedoch kurzlebige Beschwerden verspürt, darunter Schmerzen und grippeähnliche Symptome, die normalerweise einen Tag anhalten. Es ist möglich, dass die Leute planen müssen, nach dem zweiten Schuss einen Tag frei zu nehmen oder zur Schule zu gehen. Obwohl diese Erfahrungen nicht angenehm sind, sind sie ein gutes Zeichen: Sie sind das Ergebnis der Begegnung Ihres eigenen Immunsystems mit dem Impfstoff und einer starken Reaktion, die eine dauerhafte Immunität gewährleistet.

Werden mRNA-Impfstoffe meine Gene verändern?

Nein. Die Impfstoffe von Moderna und Pfizer verwenden ein genetisches Molekül, um das Immunsystem zu stärken. Dieses als mRNA bekannte Molekül wird schließlich vom Körper zerstört. Die mRNA ist in einer öligen Blase verpackt, die mit einer Zelle verschmelzen kann, so dass das Molekül hineinrutschen kann. Die Zelle verwendet die mRNA, um Proteine ​​aus dem Coronavirus herzustellen, die das Immunsystem stimulieren können. Zu jedem Zeitpunkt kann jede unserer Zellen Hunderttausende von mRNA-Molekülen enthalten, die sie produzieren, um eigene Proteine ​​herzustellen. Sobald diese Proteine ​​hergestellt sind, zerkleinern unsere Zellen die mRNA mit speziellen Enzymen. Die mRNA-Moleküle, die unsere Zellen herstellen, können nur wenige Minuten überleben. Die mRNA in Impfstoffen ist so konstruiert, dass sie den Enzymen der Zelle etwas länger standhält, sodass die Zellen zusätzliche Virusproteine ​​bilden und eine stärkere Immunantwort auslösen können. Die mRNA kann jedoch höchstens einige Tage halten, bevor sie zerstört wird.

Wenn Menschen in Entwicklungsländern aufgrund von Sperren, die erforderlich sind, um die Ausbreitung des Virus einzudämmen, arbeitslos bleiben, müssen sie weniger Geld ausgeben, was den Umsatz für Exporteure in Nordamerika, Europa und Ostasien verringert. Multinationale Unternehmen in fortgeschrittenen Ländern werden auch Schwierigkeiten haben, die erforderlichen Teile, Komponenten und Waren zu sichern.

Im Zentrum der Geschichte steht die Tatsache, dass der größte Teil des internationalen Handels keine fertigen Waren umfasst, sondern Teile, die von einem Land in ein anderes geliefert werden, um zu Produkten gefaltet zu werden. Von den Waren im Wert von 18 Billionen US-Dollar, die im vergangenen Jahr gehandelt wurden, machten sogenannte Zwischenprodukte nach Angaben der Organisation für wirtschaftliche Zusammenarbeit und Entwicklung 11 Billionen US-Dollar aus.

Die Studie stellt fest, dass die anhaltende Pandemie in armen Ländern wahrscheinlich am schlimmsten für Branchen ist, die besonders von Zulieferern auf der ganzen Welt abhängig sind, darunter Automobilindustrie, Textilindustrie, Bauwesen und Einzelhandel, in denen der Umsatz um mehr als 5 Prozent sinken könnte.

Die Ergebnisse ergänzen die Grundannahme, dass die Pandemie die Weltwirtschaft ungleicher als je zuvor machen wird, um eine komplizierende Schicht. Während dies wahr erscheint, könnte eine auffällige Form der Ungleichheit – der Zugang zu Impfstoffen – universelle Probleme aufwerfen.

In einem außergewöhnlichen Beweis für die Innovationsfähigkeit der weltweit qualifiziertesten Wissenschaftler haben einige der führenden Pharmaunternehmen in einem kleinen Bruchteil der Zeit, die für möglich gehalten wurde, lebensrettende Impfstoffe hergestellt. Aber die reichsten Länder in Nordamerika und Europa haben Bestellungen für den größten Teil des Angebots abgeschlossen – genug, um das Zwei- und Dreifache ihrer Bevölkerung zu impfen – und die armen Länder haben sich bemüht, ihren Anteil zu sichern.

Viele Entwicklungsländer, von Bangladesch über Tansania bis Peru, werden wahrscheinlich bis 2024 warten müssen, bevor sie ihre Bevölkerung vollständig impfen können.

Die Initiative, arme Länder mit zusätzlichen Ressourcen zu versorgen, gewann mit dem Amtsantritt von Präsident Biden an Bedeutung. Die Trump-Administration hat nicht zur Sache beigetragen. Dr. Anthony S. Fauci, Chief Medical Officer von Herrn Biden für die Pandemie, kündigte umgehend an, dass die Vereinigten Staaten sich der Kampagne zum Austausch von Impfstoffen anschließen würden.

Im Gegensatz zu den Billionen Dollar, die Regierungen in reichen Ländern für die Rettung von Unternehmen und Arbeitnehmern ausgegeben haben, die durch den Gesundheitsnotstand und den wirtschaftlichen Abschwung geschädigt wurden, haben die Entwicklungsländer Schwierigkeiten, darauf zu reagieren.

Da Wanderarbeitnehmer aus armen Ländern während der Pandemie Arbeitsplätze verloren haben, konnten sie nicht so viel Geld nach Hause schicken, was Ländern, die sich auf diese sogenannten Überweisungen verlassen haben, wie den Philippinen, Pakistan und Bangladesch, einen schweren Schlag versetzt.

Die globale Rezession hat die Nachfrage nach Rohstoffen gedrosselt und Kupferproduzenten wie Sambia und die Demokratische Republik Kongo sowie von Öl abhängige Länder wie Angola und Nigeria dezimiert. Da die Fälle von Covid-19 stark angestiegen sind, hat dies den Tourismus gedrückt und Arbeitsplätze und Einnahmen in Thailand, Indonesien und Marokko gekostet.

Viele arme Länder sind mit Schuldenlasten in die Pandemie eingetreten, die einen Großteil ihrer Staatseinnahmen absorbierten und ihre Ausgaben für die Gesundheitsversorgung einschränkten. Private Gläubiger haben sich geweigert, an einem bescheidenen Programm zur Aussetzung der Schulden teilzunehmen, das von der Gruppe der 20 geschmiedet wurde. Die Weltbank und der Internationale Währungsfonds versprachen beide große Erleichterungen, brachten jedoch keine nennenswerten Dollars hervor.

Auch dies scheint sich zu ändern, da eine neue Führung Washington übernimmt. Die Trump-Regierung lehnte eine geplante Ausweitung der sogenannten Sonderziehungsrechte beim IWF um 500 Milliarden US-Dollar ab, einem Reservevermögen, das die Regierungen gegen harte Währungen eintauschen können. Der Aufstieg von Herrn Biden hat die Hoffnungen der Fondsmitglieder gestärkt, dass seine Verwaltung die Expansion unterstützen wird. Demokraten im Kongress – jetzt unter Kontrolle beider Kammern – haben Unterstützung für eine Maßnahme signalisiert, die das Finanzministerium zum Handeln zwingen würde.

In Hauptstädten wie Washington und Brüssel wurde die Diskussion über die Unterstützung der Entwicklungsländer jedoch moralisch gestaltet. Führer haben darüber diskutiert, wie viel sie übrig haben können, um den am wenigsten glücklichen Gemeinschaften des Planeten zu helfen, während sie sich hauptsächlich um ihre eigenen Leute kümmern.

Die Studie fordert diesen Rahmen heraus. Wenn es nicht darum geht, dass die Menschen in den Entwicklungsländern Zugang zu Impfstoffen erhalten, schaden die Staats- und Regierungschefs der reichsten Nationen ihrem eigenen Vermögen.

“Keine Wirtschaft, wie groß sie auch sein mag, wird gegen die Auswirkungen des Virus immun sein, bis die Pandemie überall ein Ende hat”, sagte John Denton, Generalsekretär der Internationalen Handelskammer. „Der Kauf von Impfstoffen für die Entwicklungsländer ist kein Akt der Großzügigkeit der reichsten Nationen der Welt. Es ist eine wesentliche Investition für die Regierungen, wenn sie ihre Binnenwirtschaft wiederbeleben wollen. “

Categories
Business

World Well being Group holds press briefing as international locations face Covid mutations

[The stream is slated to start at 12:00 p.m. ET. Please refresh the page if you do not see a player above at that time.]

World Health Organization officials hold a press conference on the coronavirus pandemic on Monday as more countries report cases of contagious new mutations of the virus.

The Japanese National Institute of Infectious Diseases found a new variant of the coronavirus in four passengers from Brazil on Sunday. The institute said the new strain appears to have some of the same properties, such as increased infectivity, as other variations discovered in the UK and South Africa.

The United States has now found at least 63 Covid-19 cases with the new, contagious strain of the virus, first identified in the UK and known as B.1.1.7, the Centers for Disease Control and Prevention said on Friday. The variant doesn’t appear to make patients sick or increase their risk of death, health officials have said.

The coronavirus has infected more than 90.4 million people worldwide and killed at least 1.9 million people, according to Johns Hopkins University.

– CNBC’s Sam Meredith contributed to this report.

Read CNBC’s live updates for the latest news on the Covid-19 outbreak.

Categories
World News

HSBC names 2 international locations that tackled Covid and can profit in 2021

SINGAPORE – Singapore and Vietnam successfully battled coronavirus in 2020 and are likely to maintain the situation for next year, an economist said this week.

“These two countries are probably the most positive,” said HSBC Global Research’s Joseph Incalcaterra when asked which Southeast Asian countries can keep Covid under control and smoothly introduce vaccines.

Singapore “has brought its previous outbreaks under control and … at a time when most countries in the world are actually tightening restrictions, Singapore is going the opposite way,” ASEAN’s chief economist told CNBC’s “Squawk Box Asia” on Tuesday.

The city-state entered the third phase of its reopening this week and now allows gatherings of eight out of five people. Tourist attractions can increase their operating capacity from 50% to 65% once they are approved by the authorities.

People swim on a beach in East Coast Park on December 25, 2020 in Singapore.

Suhaimi Abdullah | Getty Images News | Getty Images

Incalcaterra said Singapore also has an effective vaccination strategy.

“Thanks to a relatively small population, the prospects for Singapore for 2021 are extremely good by comparison,” he said.

Prime Minister Lee Hsien Loong said there will be enough vaccines for “everyone in Singapore” by the third quarter of 2021. The country was the first in Asia to receive a shipment of Pfizer BioNTech vaccines on December 21, 2020.

HSBC’s Incalcaterra also praised Vietnam’s handling of the virus, saying its response to the pandemic enabled the country to maintain its reputation as a “very good destination” for foreign direct investment. The country has been viewed as an alternative manufacturing hub for companies looking to move out of China.

“We have seen that FDI remains very resilient in Vietnam this year,” he said.

Overall, however, Southeast Asia is unlikely to benefit from a vaccine in the near future due to logistical difficulties in rural parts of the region. “It is very unlikely that a significant portion of the population will be vaccinated in 2021,” he said.

Deep damage

Separately, Incalcaterra said Southeast Asia had been “hit very hard” this year. “From a domestic perspective, the traditional consumer motor of these economies is no longer intact.”

“We really don’t have a good view of the short-term recovery considering how deep the damage is,” he added.

While electronic exports have been “relatively bright,” HSBC is focusing on how quickly consumption and investment in the region can recover.

He said countries had “very ambitious infrastructure programs” to make the region a “reliable base for manufacturing”. These projects have stalled because of the coronavirus.

“Until the virus is under control … we won’t see this investment engine regain traction,” he said. “I think this is the biggest short-term obstacle to growth in Southeast Asia.”

Categories
World News

Covax, a world well being group, broadcasts vaccine offers to assist much less rich international locations.

Leaders of an international body promoting global access to coronavirus vaccines, known as Covax, announced on Friday that additional efforts were being made with manufacturers that would provide access to nearly two billion doses of vaccine candidates, more than that Half were intended to be shipped to low and middle income countries.

The aim of the effort is to ensure vaccination of a fifth of the population of the 190 participating countries and economies before the end of next year.

The new contracts cover vaccines that are still under study for efficacy and safety, one from AstraZeneca and the University of Oxford and one from Johnson & Johnson. As of the ongoing discussions, no agreements have been made to source the FDA-cleared BioNTech Pfizer vaccine, which is already being used in countries such as the US and the UK.

The international effort was led by the Gavi public-private health partnership, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations, and the World Health Organization.

Friday’s announcement contained the news that a mechanism had been developed for countries with overdoses to share it.

Many high-income nations have agreements with multiple manufacturers that could result in significantly more doses than are required to vaccinate their entire population. Officials from Canada and France announced that they intend to contribute their additional doses via Covax, although they have not given a schedule or say whether they would vaccinate their entire population first.

France will “start exchanging vaccines as early as possible,” said Stephanie Seydoux, the country’s ambassador for global health, at a press conference.

  • In other developments around the world:

  • in the South AfricaScientists and health officials on Friday announced the discovery of a new line of coronavirus that is rapidly dominating virus samples tested in the country. The variant, named 501.V2, has also been associated with faster spread and higher viral load in swabs in a preliminary analysis. Scientists are studying it closely because the variant contains several changes in the part of the virus that allows it to attach to human cells, which is an important target for antibody therapies and vaccines.

  • in the Europe, In the run-up to Christmas there is a patchwork of guidelines across the continent as 500,000 people die. . Germany has put a strict lockdown on Christmas week, and the Netherlands and Italy will take stricter measures during the holidays. France and Spain have some restrictions but have opposed new national bans. In the UK, Prime Minister Boris Johnson has been criticized for lifting restrictions on Christmas gatherings despite the rise in new infections. The Regional Director of the World Health Organization, Dr. Hans Henri P. Kluge said in a statement on Friday that it is not now time for Europeans to ease restrictions.

  • As coronavirus cases and hospital stays in Sweden continue to rise, the government issued several new recommendations on Friday, including the use of face masks. “We have to do more now because the medical system is tense,” said Prime Minister Stefan Lofven. The new recommendations include a limit of four people per table in restaurants, cafes and bars, as well as a ban on selling alcohol after 8 p.m. Stores, shopping centers and gyms are asked to limit the number of customers further.